These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 19367693)
1. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Shaw PJ; Fullerton AM; Scott MA; Ganey PE; Roth RA Toxicol Appl Pharmacol; 2009 May; 236(3):293-300. PubMed ID: 19367693 [TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. Shaw PJ; Ganey PE; Roth RA J Pharmacol Exp Ther; 2009 Jan; 328(1):62-8. PubMed ID: 18820134 [TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Shaw PJ; Hopfensperger MJ; Ganey PE; Roth RA Toxicol Sci; 2007 Nov; 100(1):259-66. PubMed ID: 17709330 [TBL] [Abstract][Full Text] [Related]
4. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. Shaw PJ; Ganey PE; Roth RA J Pharmacol Exp Ther; 2009 Jul; 330(1):72-8. PubMed ID: 19351866 [TBL] [Abstract][Full Text] [Related]
5. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Shaw PJ; Ditewig AC; Waring JF; Liguori MJ; Blomme EA; Ganey PE; Roth RA Toxicol Sci; 2009 Jan; 107(1):270-80. PubMed ID: 18930950 [TBL] [Abstract][Full Text] [Related]
6. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. Waring JF; Liguori MJ; Luyendyk JP; Maddox JF; Ganey PE; Stachlewitz RF; North C; Blomme EA; Roth RA J Pharmacol Exp Ther; 2006 Mar; 316(3):1080-7. PubMed ID: 16299187 [TBL] [Abstract][Full Text] [Related]
7. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice. Giustarini G; Kruijssen L; van Roest M; Bleumink R; Weaver RJ; Bol-Schoenmakers M; Smit J; Pieters R J Appl Toxicol; 2018 May; 38(5):753-765. PubMed ID: 29377180 [TBL] [Abstract][Full Text] [Related]
8. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Shaw PJ; Beggs KM; Sparkenbaugh EM; Dugan CM; Ganey PE; Roth RA Toxicol Sci; 2009 Oct; 111(2):288-301. PubMed ID: 19638433 [TBL] [Abstract][Full Text] [Related]
9. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Luyendyk JP; Maddox JF; Green CD; Ganey PE; Roth RA Hepatology; 2004 Dec; 40(6):1342-51. PubMed ID: 15565632 [TBL] [Abstract][Full Text] [Related]
10. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Giustarini G; Huppelschoten S; Barra M; Oppelt A; Wagenaar L; Weaver RJ; Bol-Schoenmakers M; Smit JJ; van de Water B; Klingmüller U; Pieters RHH Toxicol Appl Pharmacol; 2020 Mar; 391():114915. PubMed ID: 32035082 [TBL] [Abstract][Full Text] [Related]
11. Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Liguori MJ; Ditewig AC; Maddox JF; Luyendyk JP; Lehman-McKeeman LD; Nelson DM; Bhaskaran VM; Waring JF; Ganey PE; Roth RA; Blomme EA Int J Mol Sci; 2010 Nov; 11(11):4697-714. PubMed ID: 21151465 [TBL] [Abstract][Full Text] [Related]
12. Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase. Poulsen KL; Albee RP; Ganey PE; Roth RA J Pharmacol Exp Ther; 2014 May; 349(2):185-91. PubMed ID: 24525298 [TBL] [Abstract][Full Text] [Related]
13. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related. Beggs KM; Maiuri AR; Fullerton AM; Poulsen KL; Breier AB; Ganey PE; Roth RA Toxicology; 2015 May; 331():35-46. PubMed ID: 25748550 [TBL] [Abstract][Full Text] [Related]
14. Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. Poulsen KL; Olivero-Verbel J; Beggs KM; Ganey PE; Roth RA J Pharmacol Exp Ther; 2014 Jul; 350(1):164-70. PubMed ID: 24817034 [TBL] [Abstract][Full Text] [Related]
15. Roles of the hemostatic system and neutrophils in liver injury from co-exposure to amiodarone and lipopolysaccharide. Lu J; Roth RA; Malle E; Ganey PE Toxicol Sci; 2013 Nov; 136(1):51-62. PubMed ID: 23912913 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. Deng X; Luyendyk JP; Zou W; Lu J; Malle E; Ganey PE; Roth RA J Pharmacol Exp Ther; 2007 Aug; 322(2):852-61. PubMed ID: 17505017 [TBL] [Abstract][Full Text] [Related]
18. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Zou W; Devi SS; Sparkenbaugh E; Younis HS; Roth RA; Ganey PE Toxicol Sci; 2009 Mar; 108(1):184-93. PubMed ID: 19074762 [TBL] [Abstract][Full Text] [Related]
19. TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Ahn JH; Jegal H; Choi MS; Kim S; Park SM; Ahn J; Han HY; Cho HS; Yoon S; Oh JH Toxicol Lett; 2021 May; 342():73-84. PubMed ID: 33609687 [TBL] [Abstract][Full Text] [Related]
20. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement. Giustarini G; Vrisekoop N; Kruijssen L; Wagenaar L; van Staveren S; van Roest M; Bleumink R; Bol-Schoenmakers M; Weaver RJ; Koenderman L; Smit J; Pieters R Toxicol Sci; 2019 Feb; 167(2):385-396. PubMed ID: 30247740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]